U.S. cervical cancer screening trial IDs prevalence of abnormal cytology, high-risk HPV, ≥CIN2
WEDNESDAY, Dec. 28 (HealthDay News) -- Estimates of the baseline prevalence of cytologic abnormalities, high-risk human papillomavirus (hrHPV; defined as 1 of 14 high-risk types of HPV including HPV 16 and HPV 18), HPV 16, HPV 18, and cervical intraepithelial neoplasia grade 2 (CIN2) or greater have been established using the Addressing the Need for Advanced HPV Diagnostics screening trial, according to a study published in the January issue of the American Journal of Obstetrics & Gynecology.
Thomas C. Wright Jr., M.D., from Columbia University in New York City, and colleagues describe the baseline data from a prospective, multicenter U.S. cervical cancer screening trial. Liquid-based cytology and HPV testing were performed for 47,208 women (aged 21 years or older) undergoing routine screening. Colposcopy was performed for women with abnormal cytology, for women who were hrHPV-positive, and for a random subset of women who were 25 years or older and had negative cytology and HPV tests.
The investigators found that the prevalence of cytologic abnormalities was 7.1 percent. The cobas HPV Test detected hrHPV in 12.6 percent of women, HPV 16 in 2.8 percent, and HPV 18 in 1.0 percent of women. With increasing age, there was a decrease in both cytologic abnormalities and hrHPV positivity. The adjusted prevalence of CIN2 or greater decreased from 2.3 percent in women aged 25 to 34 years to 1.5 percent among older women.
"The Addressing the Need for Advanced HPV Diagnostics study provides important estimates of the prevalence of cytologic abnormalities, hrHPV positivity, and CIN2 or greater in a U.S. screening population," the authors write.
Several authors disclosed financial relationships with pharmaceutical and diagnostic companies, including Roche Molecular Systems, which partially funded the study.
Full Text (subscription or payment may be required)